Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Abstract

BACKGROUND Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess efficacy, safety, and tolerability of novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide monotherapy versus placebo in people with type 2 diabetes inadequately controlled by diet and exercise alone. METHODS We did a 40-week, double-blind, randomised, placebo-controlled, phase 3 trial (SURPASS-1), at 52 medical research centres and hospitals in India, Japan, Mexico, and the USA. Adult participants (≥18 years) were included if they had type 2 diabetes inadequately controlled by diet and exercise alone and if they were naive to injectable diabetes therapy. Participants were randomly assigned (1:1:1:1) via computer-generated random sequence to once a week tirzepatide (5, 10, or 15 mg), or placebo. All participants, investigators, and the sponsor were masked to treatment assignment. The primary endpoint was the mean change in glycated haemoglobin (HbA1c) from baseline at 40 weeks. This study is registered with ClinicalTrials.gov, NCT03954834. FINDINGS From June 3, 2019, to Oct 28, 2020, of 705 individuals assessed for eligibility, 478 (mean baseline HbA1c 7·9% [63 mmol/mol], age 54·1 years [SD 11·9], 231 [48%] women, diabetes duration 4·7 years, and body-mass index 31·9 kg/m2) were randomly assigned to tirzepatide 5 mg (n=121 [25%]), tirzepatide 10 mg (n=121 [25%]), tirzep…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01324-6

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

37 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 22 references

Research works printed but not linked: 2

  1. Cosgrove, 2020, Tirzepatide, a dual GIP and GLP-1 receptor agonist, mediates its anorectic effect in preclinical models of obesity due to a reduction in homeostatic and hedonic related feeding, Diabetologia, 63, 1
  2. Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1

Cited by

See all 1,080

Metadata

Authors
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T.
Affiliations
  • Dallas Diabetes Research Center (US)
  • Rockwood Clinic (US)
  • National Research Institute (US)
  • Takatsuki Red Cross Hospital (JP)
  • Eli Lilly (United States) (US)
Corresponding author
Rosenstock, Julio
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-07
Volume
398
Issue
10295
Pages
143-155
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3177393241
Cited by
1,080
References
22
Citations by year
2026: 208 · 2025: 260 · 2024: 219 · 2023: 217 · 2022: 127 · 2021: 47
FWCI
114.12
Type
journal article
Language
en
Update notices
erratum (2021-07-17)
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, type 2 diabetes, GIP/GLP-1 receptor agonist, HbA1c, glycemic control, monotherapy, drug safety and tolerability, inadequate glycemic control, dose comparison, adverse events, hypoglycemia
MeSH terms
Tirzepatide, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, India, Japan, Male, Middle Aged, North America, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01324-6
The paper
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)01324-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.